The ZINFORO® Patient

Ceftaroline fosamil (Zinforo^®): cSSTI Patient profiles

Identifying a cSSTI patient who may benefit from Zinforo^®

In cSSTI patients, initial antimicrobial therapy failure is associated with 4-11 days longer in hospital and 4-12x higher mortality^2·4

Please note: The examples described here are not actual patients, but fictitious representations of scenarios for which Ceftaroline fosamil (Zinforo^®) could be considered.

^tRefer to Local product Document for further information on Zinforo.¹

BMI: body mass index; CrCl: creatinine clearance; Cssti: complicated skin and soft tissue infections; DM: diabetes mellitus; HbA1c: hemoglobin A1c; ICU: intensive care unit; MRSA: methicillin-resistant Staphylococcus aureus; RR: respiratory rate; UTI: urinary tract infection.

References:
1. ZINFORO^® (ceftaroline fosamil). Local Product Document of Ceftaroline; LPDZIN072021;
2. Berger A, et al. Surg Infect 2013;14;304-12;
3. Edelsberg J, et al. Infect Control Hosp Epidemiol 2008;29:160-9;
4. Ostermann H, et al. J Med econ 2013;17:719-29.

How do you identify your Zinforo^® patients with cSSTI?^*1-5

Zinforo^® cSSTI patient profiles^*6,7

Patient 1: Diabetic patient with cSSTI

A 62-year-old female with diabetes presents with deep and extensive cellulitis on the right leg that extends from mid-calf to the ankle.

Patient presentation, history and risk factors

• Tender, erythematous, non-raised skin lesions
• Rapid spread of infection over the past 24 hours
• Patient weight = 102 kg
• BMI = 36 kg/m²
• Elevated blood cholesterol
• HbA1c = 7.4%
• History of smoking
• Lives in a nursing home
• Recent use of an old cephalosporin for a skin lesion 3 weeks ago

Patient 2: cSSTI patient with renal insufficiency^

A 67-year-old male presents with a painful, fluctuant and gluteal abscess.

Patient presentation, history and risk factors:

• Rapidly spreading infection
• Patient is deteriorating; may be required to be moved to the ICU in the next 24 hours
• Severe renal insufficiency (CrCl at hospital admission: 17 mL/min)
• CrCl falling rapidly
• History of renal disease
• History of prior antibiotic use

Please note: The examples described here are not actual patients, but fictitious representations of the scenarios for which Zinforo® could be considered.

*There is no experience with Zinforo^® in the treatment of cSSTI in the following patient groups:
The immunocompromised, patients with severe sepsis/septic shock, necrotising fasciitis, perirectal abscess and patients with third-degree and extensive burns. There is limited experience in treating patients with diabetic foot infections. Caution is advised when treating such patients.⁸

^Zinforo^® is primarily excreted by the kidneys and the dose should be reduced in patients with moderate to severe renal insufficiency. ⁸

cSSTI: complicated skin and soft tissue infections; BMI: body mass index; CrCl: creatinine clearance; HbA1c: hemoglobin A1c; ICU: intensive care unit.

References:
1. Corey G, Wilcox M, Talbot G, et al. Clin Infect Dis 2010; 51:641–50.
2. Santos PD, Davis A, Jandourek A, et al. J Chemother 2013;25:341–6.
3. Stein GE, Wallace S, Jandourek A, et al. Ceftaroline fosamil for treatment of cSSTI due to Staphylococcus aureus with vancomycin MICs of 1.5 to 2 mg/L: CAPTURE Study Experience.
4. Corey G, Wilcox M, Talbot G, et al. J Antimicrob Chemother 2010;65(Suppl. 4):iv41–iv51.
5. Wilcox M, Corey G, Talbot G, et al. J Antimicrob Chemother 2010;65(Suppl. 4):iv53–iv65. Evans J, Udeani G, Cole P, et al. Postgrad Med 2014; 126:128–34.
6. Maggiore C, Pasquale T, Cole P, et al. Expert Rev Clin Pharmacol 2015; 8:141–53.
7. Lipsky BA, Cannon CM, Ramani A, et al. Diabetes Metab Res Rev 2015; 31:395–401.
8. ZINFORO^® (ceftaroline fosamil). Local Product Document of Ceftaroline; LPDZIN072021.